Mathias Svahn - NextCell Pharma Founder CEO
| NXTCL Stock | SEK 1.69 0.01 0.60% |
Insider
Mathias Svahn is Founder CEO of NextCell Pharma AB
| Age | 47 |
| Phone | 46 87 35 55 95 |
| Web | https://www.nextcellpharma.com |
NextCell Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1747) % which means that it has lost $0.1747 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2957) %, meaning that it generated substantial loss on money invested by shareholders. NextCell Pharma's management efficiency ratios could be used to measure how well NextCell Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Samuel Wagner | Xbrane Biopharma AB | N/A | |
| Christer Mller | BioArctic AB | 64 | |
| Associate Gier | Xbrane Biopharma AB | N/A | |
| Harald Borgeke | BioArctic AB | N/A | |
| Pr Lannfelt | BioArctic AB | 74 | |
| Oskar Bosson | BioArctic AB | 47 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Frida Lekander | BioArctic AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Nina Ivers | Xbrane Biopharma AB | 53 | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Anette Lindqvist | Xbrane Biopharma AB | 57 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Maria Edebrink | Xbrane Biopharma AB | 54 | |
| Jan Mattsson | BioArctic AB | 63 | |
| David Vikstrm | Xbrane Biopharma AB | 46 | |
| Gunilla Osswald | BioArctic AB | 62 | |
| Johanna Flting | BioArctic AB | 51 | |
| Gunilla Andersson | BioArctic AB | 62 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
Management Performance
| Return On Equity | -0.3 | |||
| Return On Asset | -0.17 |
NextCell Pharma AB Leadership Team
Elected by the shareholders, the NextCell Pharma's board of directors comprises two types of representatives: NextCell Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NextCell. The board's role is to monitor NextCell Pharma's management team and ensure that shareholders' interests are well served. NextCell Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NextCell Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sofie Jansson, Marketing Director | ||
| Mathias Svahn, Founder CEO | ||
| Anders MSc, Chairman | ||
| Edvard Smith, Medical Director | ||
| Patrik Fagerholm, Chief Officer | ||
| Lindsay Davies, Chief Officer |
NextCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NextCell Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (4.75) % | |||
| Current Valuation | 134.94 M | |||
| Shares Outstanding | 34.38 M | |||
| Shares Owned By Insiders | 42.82 % | |||
| Shares Owned By Institutions | 5.27 % | |||
| Price To Book | 2.01 X | |||
| Price To Sales | 37.14 X | |||
| Revenue | 5.59 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.